Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)

Korábbi kezelés

• 9、Drug or alcohol abuse

Más betegség

• 1、History of other malignancies within 3 years
• 3、Active autoimmune disease, which needs systemic therapy
• 4、Uncontrolled infection, which needs systemic therapy
• 5、History of allogeneic tissue/solid organ transplant
• 6、Serious illness, such as severe mental disorders, cardiac disease, coagulation disorders, digestive system disease, etc
• 7、Active HBV, HCV, or HIV infection

Egyéb

• 2、Participate in other clinical trials at the same time
• 8、Pregnant or lactating female patients
• 10、 Unable or unwilling to sign the informed consent

• 1、Written informed consent
• 2、18-70 years old
• 3、Adequate organ function and ECOG of 0 ~1
• 4、Without systemic therapy at the time of enrollment
• 5、FIGO 2018 stage IB3, IIA2, or IIIC1r
• 6、Histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix
• 7、Measurable lesions could be defined by RECIST v1.1
• 8、Willing to get blood/ tumor tissue tested
• 9、Patients who observed the rules about the scheduled visit, study schedule, and medical examination
• 10、The function of major organs is normal, and the following criteria are met:
• 10.1 Blood routine examination must meet: (no blood transfusion within 14 days)
  • Hb≥90g/L:
  • ANC≥1.5x10\^9/L; PLT≥100x10\^9/L;
• 10.2 The biochemical examination must meet the following standards BIL < 1.5 × ULN; ALT and AST < 2.5xULN; ALB≥ 28 g/L
• 11、Patients who are willing and able to comply with visiting arrangements, treatment plans, laboratory tests, and other research procedures.